



ABN 16 088 212 088

PO Box 139
Fyshwick Canberra ACT
2609 Australia

Tel +61 2 6280 8535
Fax +61 2 6280 8538

www.itl-limited.com

Market release: 19 November 2004

ITL resolves patent dispute in Europe

ITL has resolved its pending patent/licensing dispute with Fresenius/NPBI.

Fresenius/NPBI had commenced revocation proceedings against the APIS patent acquired by ITL in 2003 as outlined in Contingent Liabilities section of ITL's 2004 Annual Report (page 40, Note 29: APIS Needle Assembly).

The successful outcome is that Fresenius/NPBI has taken a license from ITL for the term of the patent and will now terminate legal proceedings. Details of the licensing agreement are confidential.

ITL's CEO, Bill Mobbs, says "it's the best possible outcome for us. We have moved from litigation to partnership. We're now looking forward to building a productive working relationship with Fresenius/NPBI, a relationship that will benefit both companies and their shareholders."

ITL (ASX: ITD, www.itl-limited.com) specialises in creating medical devices and procedure kits for global healthcare markets. ITL manufactures in Australia and Malaysia, exports into 35 countries and has representative offices in North America, Europe, and Asia. ITL supplies 160 private and public hospitals across Australia with its range of customised Procedure Packs and Kits.

For more information contact:

Bill Mobbs
Chief Executive Officer
Ph: 02 6280 8535
bill.mobbs@itl-limited.com